Search

Your search keyword '"Varaldo, R"' showing total 188 results
Start Over Author "Varaldo, R"
188 results on '"Varaldo, R"'

54. Il nuovo modello nazionale di commercio

Author

Varaldo, R., Varaldo, Riccardo, Fornari, Daniele, Fornari, Daniele (ORCID:0000-0002-7043-693X), Varaldo, R., Varaldo, Riccardo, Fornari, Daniele, and Fornari, Daniele (ORCID:0000-0002-7043-693X)

Published
1999

79. Imatinib 600 mg in the treatment of chronic myeloid leukemia in accelerated phase and in blast crisis. Results of a multicentric prospective study of the GIMEMA working party of civil in the long term

Author

FRANCESCA PALANDRI, Castagnetti, F., Testoni, N., Luatti, S., Bassi, S., Alimena, G., Miccolis, C., Falzetti, F., Merante, S., Abruzzese, E., Liberati, A. M., Varaldo, R., Schiamone, E. M., Tiribelli, M., Bocchia, M., Zuffa, E., Martino, B., Avanzino, P., Saglio, G., Martinelli, G., Baccarani, M., and Rosti, Gianantonio

88. INTRA-BONE MARROW (IBM) TRANSPLANT OF CORD BLOOD CELLS IS ASSOCIATED WITH BETTER ENGRAFTMENT, FASTER PLATELET RECOVERY AND LESS SEVERE AGVHD AS COMPARED WITH INTRAVENOUS ADMINISTRATION. AN EUROCORD MATCHED PAIRED ANALYSIS

Author

Frassoni, F., Labopin, M., Podesta, M., Gualandi, F., Sanchez-Guijo, F., Fagioli, F., Rovira, M., ANNA MARIA RAIOLA, Ubezio, G. L., Varaldo, R., Berger, M., Nesi, F., Carreras, E., Caballero, D., Ionescu, I., Gobbi, M., Sambuceti, G. M., Sacchi, N., Bacigalupo, A., Gluckman, E., and Rocha, V.

94. Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature.

Author

Fornaro, G., Del Bono, V., Nicolini, L.A., Viscoli, C., Mikulska, M., Tatarelli, P., Raiola, A.M., Gualandi, F., Varaldo, R., Angelucci, E., Di Muccio, T., Gramiccia, M., and Gradoni, L.

Subjects
*BONE marrow, *FEVER, *LEISHMANIA, *PANCYTOPENIA, *VISCERAL leishmaniasis
Abstract

Abstract Visceral leishmaniasis has been recognized as an opportunistic infection affecting people with cellular-immunity impairment, including hematopoietic cell transplantation (HCT) recipients. We describe the case of a young Italian man with Hodgkin lymphoma, who developed visceral leishmaniasis after multiple lines of chemotherapy and allogenic HCT. Literature review of visceral leishmaniasis in HCT recipients was also performed. Eleven patients (median age 50 years, 9 male) developed visceral leishmaniasis after allogenic (n = 9) and autologous (n = 2) HCT. Most of them presented with fever and pancytopenia. Bone marrow examination was the main diagnostic technique; liposomal amphotericin B was the treatment of choice. Four out of eight patients (for whom data are available) experienced visceral leishmaniasis relapse. Visceral leishmaniasis in HCT recipients is a rare event that should be suspected in patients with persistent fever, pancytopenia and possible exposure to Leishmania spp., remembering that – as well as South-East Asia, East Africa and South America - it is endemic in several European regions. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

95. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab

Author

Edoardo Benedetti, Carlo Borghero, Francesca Gualandi, Anna Paola Iori, Mattia Algeri, Carmen Di Grazia, Patrizia Chiusolo, Maurizio Musso, Carmine Selleri, Antonio M. Risitano, Anna Maria Raiola, Francesca Bonifazi, Massimo Martino, Alice Bertaina, Francesco Onida, Emanuele Angelucci, Alessandro Rambaldi, Riccardo Varaldo, Andrea Bacigalupo, Simona Sica, Franco Locatelli, Francesco Zallio, Fabio Ciceri, Lucia Prezioso, Matteo Parma, Bacigalupo, A., Angelucci, E., Raiola, A. M., Varaldo, R., Di Grazia, C., Gualandi, F., Benedetti, E., Risitano, A., Musso, M., Zallio, F., Ciceri, F., Chiusolo, P., Sica, S., Rambaldi, A., Bonifazi, F., Parma, M., Martino, M., Onida, F., Iori, A. P., Selleri, C., Borghero, C., Bertaina, A., Prezioso, L., Algeri, M., and Locatelli, F.

Subjects
Adult, medicine.medical_specialty, medicine.drug_class, Graft vs Host Disease, Monoclonal antibody, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Acute graft versus host disease, medicine, Humans, Prospective Studies, Treatment of steroid resistant acute graft versus, Stage (cooking), Adverse effect, Prospective cohort study, Transplantation, biology, business.industry, Hematopoietic Stem Cell Transplantation, Compassionate Use, Antibodies, Monoclonal, Hematology, Steroid resistant, Settore MED/15 - MALATTIE DEL SANGUE, begelomab, methylprednisolone, acute respiratory failure, 030220 oncology & carcinogenesis, Acute Disease, biology.protein, Steroids, Antibody, business, treatment of steroid resistant acute graft versus host disease with an anti cd26 monoclonal antibody begelomab, 030215 immunology
Abstract

We have treated 69 patients with steroid refractory acute graft versus host disease (SR-aGvHD), with an anti-CD26 monoclonal antibody (Begelomab): 28 patients in two prospective studies (EudraCT No. 2007-005809-21; EudraCT No. 2012-001353-19), and 41 patients on a compassionate use study. The median age of patients was 42 and 44 years; the severity of GvHD was as follows: grade II in 8 patients, grade III in 33, and grade IV in 28 patients. There were no adverse events directly attributable to the antibody. Day 28 response was 75% in the prospective studies and 61% in the compassionate use patients, with complete response rates of 11 and 12%. Response for grade III GvHD was 83 and 73% in the two groups; response in grade IV GvHD was 66 and 56% in the two groups. Non relapse mortality (NRM) at 6 months was 28 and 38%. Overall there were 64, 56, 68% responses for skin, liver, and gut stage 3-4 GvHD. The overall survival at 1 year was 50% for the prospective studies and 33% for the compassionate use patients. In conclusion, Begelomab induces over 60% responses in SR-aGvHD, including patients with severe gut and liver GvHD, having failed one or more lines of treatment.

Published
2020

97. Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa

Author

Samantha Biasco, Mauro Spriano, Ivana Pierri, Maurizio Miglino, Marco Gobbi, Angelo Michele Carella, Enrico Balleari, Francesca Olcese, Riccardo Varaldo, Sara Aquino, Nicoletta Colombo, Chiara Ghiggi, Anna Ghiso, Marino Clavio, Raffaella Grasso, Mario Sessarego, Clavio, M, Ghiso, A, Ghiggi, C, Spriano, M, Colombo, N, Grasso, R, Varaldo, R, Miglino, M, Pierri, I, Olcese, F, Aquino, S, Biasco, S, Balleari, E, Carella, A, Sessarego, M, and Gobbi, M

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Adolescent, Long term follow up, Salvage therapy, Antineoplastic Agents, Tretinoin, Biology, Fluorescent in situ hybridization, Leukemia, Promyelocytic, Acute, Recurrence, Internal medicine, medicine, Humans, Aged, Retrospective Studies, Aged, 80 and over, All-trans retinoic acid, Complete remission, Cancer, Retrospective cohort study, PML-RARα, General Medicine, Middle Aged, medicine.disease, Molecular medicine, Acute promyelocytic leukaemia, Oncology, Female, Follow-Up Studies, medicine.drug
Abstract

We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients. Induction and consolidation therapy were well-tolerated by most patients. Of the 79 patients who were initially treated with the all-trans retinoic acid (ATRA)-containing regimens, there were 3 haemorrhagic deaths during the first period of therapy (4%) and one in consolidation which was due to infection. Following consolidation, molecular assessment of response was performed on 67 patients, and 66 were found to have achieved cytogenetic and molecular remission (98%). After a median follow-up of 100 months (12-192), 10 of the 75 patients who achieved complete remission (13%) relapsed. Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009). Sixty-nine patients were in molecular remission after first-line and/or salvage therapy (74%). To date, 4 patients out of the 91 have undergone salvage allogeneic transplant (4%).

Published
2009

98. Strategie di creazione del valore: Calligaris

Author

Pegan, Giovanna, Sambri, C., Varaldo R., Dalli D., Resciniti R., Tunisini A. (a cura di), Pegan, Giovanna, and Sambri, C.

Subjects
Calligari, distretto, valore, Calligaris, strategie competitive, media impresa
Abstract

Questo lavoro intende approfondire due specifiche aree tematiche strettamente interconnesse: le strategie competitive che consentono ad una media impresa distrettuale, come Calligaris, di creare valore aggiunto rispetto ai concorrenti in un contesto economico globale; i rapporti con un mercato di sbocco, come quello dell'arredo, che si presenta altamente frammentato e complesso, anche considerata la natura del prodotto commercializzato, e del processo d’acquisto ad esso sotteso.

Published
2009

99. Strategie di nicchia e rapporti con il mercato: Modiano

Author

DE LUCA, PATRIZIA, VARALDO R., DALLI D., RESCINITI R., TUNISINI A. (a cura di), TUNISINI A., and DE LUCA, Patrizia

Subjects
Internazionalizzazione, Medie imprese, Carte da gioco, Modiano, Strategie di nicchia
Abstract

Il capitolo, nell'ambito del libro che valorizza la crescita delle medie imprese italiane, propone una lettura del caso Modiano secondo diverse prospettive: imprenditoriale, competitiva ed organizzativa. Cercando di cogliere diversi spunti di riflessione e confronto tra contributi teorici e prassi aziendale, vengono trattati diversi temi, quali il ciclo di vita dell'impresa, la transizione imprenditoriale, le scelte strategiche nei settori maturi, le strategia di nicchia e focalizzazione, la gestione dei rapporti con il mercato.

Published
2009

100. Strategie competitive tra innovazione e internazionalizzazione: Gruppo Principe

Author

NANUT, VLADIMIR, VIANELLI, DONATA, Varaldo R., Dalli D., Resciniti R., Tunisini A., Nanut, Vladimir, and Vianelli, Donata

Subjects
Internazionalizzazione, Principe, Mercati maturi, Medie imprese
Abstract

Nell'ambito del libro che valorizza la crescita delle medie imprese italiane, il capitolo affronta il caso Principe. L'azienda triestina opera in un mercato maturo, affrontando con successo le problematiche di innovazione e internazionalizzazione.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results